Immune-Onc Therapeutics

Executive Summary

Immune-Onc Therapeutics is a private biopharmaceutical company headquartered in Palo Alto, California, pioneering novel immunotherapies that target myeloid cells to treat cancer and autoimmune diseases. Founded in 2016, the company is leveraging deep expertise in myeloid biology to develop first-in-class antibodies against inhibitory myeloid checkpoints, with the goal of unlocking anti-tumor immunity in patients who do not respond to conventional T-cell-based immunotherapies. Immune-Onc’s lead candidate, IO-108, is a monoclonal antibody targeting LILRB2 (a myeloid immune checkpoint) and is currently in Phase 1 clinical development for solid tumors. The company’s pipeline also includes preclinical programs targeting other myeloid receptors for both oncology and autoimmune indications. By focusing on the under-explored myeloid axis, Immune-Onc aims to address significant unmet medical needs and expand the benefit of immunotherapy to a broader patient population.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for IO-108 in advanced solid tumors40% success
• Q4 2026IND filing for a novel myeloid checkpoint inhibitor (IO-202 or IO-108 combination)70% success
• H2 2026Strategic partnership or licensing agreement for IO-108 in a specific indication30% success